Novo Nordisk's oral semaglutide product faces market scrutiny as its compounded supply relies entirely on Chinese API sources.
1 report, 1 independent
Updated May 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk's oral semaglutide product faces market scrutiny as its compounded supply relies entirely on Chinese API sources.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major drug manufacturers like Eli Lilly and Novo Nordisk faced price slashes due to federal mandates, alongside California healthcare initiatives.Also in this story
- Gavin Newsom is leveraging state power to fund generic drug development, challenging major pharmaceutical manufacturers.
- Budget plan includes cuts to contend with funding loss for the state healthcare system, impacting Medi-Cal beneficiaries.